Figure 1.
![Figure 1. Nonmyeloablative ex vivo T-cell depleted (TCD) peripheral blood stem cell transplantation (PBSCT) and delayed donor lymphocyte infusion (DLI) for hematologic malignancy. . / This schematic representation of a nonmyeloablative conditioning regimen (cyclophosphamide ± fludarabine, anti-CD2 monoclonal antibody [MEDI-507], and thymic irradiation) shows the induction of mixed lymphohematopoietic chimerism followed by delayed DLI to convert the chimerism to full donor, thereby capturing a potent graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD). The graph from one patient shows “split lineage” chimerism and conversion of T-cell chimerism following DLI. BMT, bone marrow transplantation.](https://ash.silverchair-cdn.com/ash/content_public/journal/hematology/2005/1/10.1182_asheducation-2005.1.390/2/spitzer_fig1.jpeg?Expires=1735587779&Signature=W0HpY9IgJ2tFOH3sksCLLNZhsCM1lbWVSrxmbHICT0Hti~Gko1cvmYu7LMiIiOSzTRhEzu~8h1sD7PcTqR3iaF~-GPQgvvCkSF06o5vrOKsqvgsg9TIYgBNUYE8rT0bPK4OWXvM0LpSO0JSXFWmBI0j1ZIzZZVv32in9U7SzQuKo32aOCHLLnQHP5MbbA~2k-KehpHuyoj0z4alGUDZKJSAREPA5gkBo-xYXsaauTaktcGIodA4Qz2HATNAQBK5Bk6T80szPdRRScRXArnFgQaDamO6-RK1m8Uf1Q7ZE~sW7HIo5367IgDN-TcyffSw2POujTHFv3XftDnR3Ar~7tQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Nonmyeloablative ex vivo T-cell depleted (TCD) peripheral blood stem cell transplantation (PBSCT) and delayed donor lymphocyte infusion (DLI) for hematologic malignancy.
This schematic representation of a nonmyeloablative conditioning regimen (cyclophosphamide ± fludarabine, anti-CD2 monoclonal antibody [MEDI-507], and thymic irradiation) shows the induction of mixed lymphohematopoietic chimerism followed by delayed DLI to convert the chimerism to full donor, thereby capturing a potent graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD). The graph from one patient shows “split lineage” chimerism and conversion of T-cell chimerism following DLI. BMT, bone marrow transplantation.
